Could daratumumab be used to treat severe allergy?

J Allergy Clin Immunol. 2017 May;139(5):1677-1678.e3. doi: 10.1016/j.jaci.2016.12.955. Epub 2017 Jan 19.

Authors

Mark A Blankestijn¹, Niels W C J van de Donk², Kate Sasser³, André C Knulst⁴, Henny G Otten⁵

Affiliations

¹ Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: m.a.blankestijn@umcutrecht.nl.
² Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
³ Janssen Research & Development, Spring House, Pa.
⁴ Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
⁵ Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

PMID: 28109726
DOI: 10.1016/j.jaci.2016.12.955

No abstract available

Publication types

Letter

MeSH terms

ADP-ribosyl Cyclase 1 / immunology
Animals
Antibodies, Monoclonal / therapeutic use*
Antigens, Dermatophagoides / immunology
Betula / immunology
Drug Approval
Humans
Hypersensitivity / immunology
Hypersensitivity / therapy*
Immunoglobulin E / blood
Immunotherapy / methods*
Multiple Myeloma / immunology
Multiple Myeloma / therapy*
Netherlands
Plasma Cells / drug effects
Plasma Cells / immunology*
Pollen / immunology
Pyroglyphidae / immunology

Substances

Antibodies, Monoclonal
Antigens, Dermatophagoides
Immunoglobulin E
daratumumab
ADP-ribosyl Cyclase 1